Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.41 |
| ▸ | WNT3A | P56704 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237393 | 0.88 | HPGD (0.50) | MAOBSLC22A12HPGDPTPN1NR4A2 | |
| SCHEMBL2088041 | 0.87 | HPGD (0.49) | MAOBSLC22A12HPGDPTPN1NR4A2 | |
| SCHEMBL2089649 | 0.87 | HPGD (0.49) | MAOBSLC22A12HPGDPTPN1NR4A2 | |
| SCHEMBL1719411 | 0.87 | MAOB (0.45) | MAOBSLC22A12LMNAMAPTHPGD | |
| Potassium SCHEMBL2089657 | 0.87 | HPGD (0.49) | MAOBSLC22A12HPGDPTPN1NR4A2 | |
| SCHEMBL2088037 | 0.87 | HPGD (0.49) | MAOBSLC22A12HPGDPTPN1NR4A2 | |
| SCHEMBL2184379 | 0.86 | MAOB (0.46) | MAOBSLC22A12LMNAMAPTHPGD | |
| Potassium Ion SCHEMBL2089653 | 0.86 | PTPN1 (0.45) | MAOBSLC22A12LMNAMAPTHPGD | |
| SCHEMBL2088038 | 0.86 | PTPN1 (0.45) | MAOBSLC22A12LMNAMAPTHPGD | |
| SCHEMBL1135054 | 0.85 | THRA (0.44) | MAOBSLC22A12LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166233-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-07-07 | — | — | US | claimed |
| US-20090176885-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-07-09 | — | — | US | claimed |
| EP-1978948-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007092729-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-16 | — | — | WO | claimed |
| US-20110166233-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20090176885-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1978948-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007092729-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166233-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, CPT1A, GPR119 | MAOB 4523/4885SLC22A12 1864/4885LMNA 2620/4885 |
| US-20090176885-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, CPT1A, FABP1 | MAOB 4567/4885SLC22A12 1880/4885LMNA 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.